Beta-defensin 116

Also known as: Beta-defensin 16, Defensin, beta 116, DEFB116, Q30KQ4

Beta-defensin 116 (DEFB116) is an antimicrobial peptide belonging to the beta-defensin family, characterized by a conserved six-cysteine motif that forms three disulfide bridges. Its primary mechanism of action involves direct disruption of bacterial cell membranes through electrostatic interactions with negatively charged microbial surfaces, leading to membrane permeabilization and cell death. This peptide exhibits broad-spectrum antibacterial activity, targeting both Gram-positive and Gram-negative bacteria, though specific bacterial strains and potency remain under investigation due to limited experimental data. Current research on DEFB116 is at an early, experimental stage, with only one indexed PubMed reference available. Preliminary findings suggest its expression may be tissue-specific, potentially in epithelial surfaces, and its antimicrobial efficacy may be influenced by salt concentration and pH, similar to other beta-defensins. No in vivo or clinical studies have been reported, and its role in host defense or immune modulation beyond direct antibacterial action has not been characterized. Given the scarcity of published data, the clinical relevance of DEFB116 is not yet established. It represents a candidate for future therapeutic development against bacterial infections, particularly in contexts of antibiotic resistance, but requires substantial validation through mechanistic, preclinical, and safety studies before any translational application can be considered. For research purposes only — not medical advice.

Key data

Mechanism of action

Has antibacterial activity

Research & studies

Frequently asked questions

Related peptides